DC Leads Nation in Prostate Cancer
Race and Distrust Leading Factors in Death Rate WASHINGTON, March 8, 2012 /PRNewswire-USNewswire/ -- Increased risk for African-Americans, medical distrust and negative attitudes toward testing contribute to high rates of prostate cancer in the District of Columbia.

The Prostate Cancer Foundation Builds Momentum in China
NEW YORK, Feb. 22, 2012 /PRNewswire/ -- Leading U.S. prostate cancer surgeon, Dr. David Samadi often takes time from the operating room in New York City to join the prostate cancer fight overseas. As a robotic surgery and robotic prostatectomy expert, his knowledge and hands-on support is a vital part of the growth and development of international prostate cancer treatment efforts in countries such as the Netherlands, France, Dominican Republic and Israel.

PSA Test Reduces Prostate Cancer Deaths
NEW YORK, March 7, 2012 /PRNewswire/ -- Good news for those in favor of the one and only prostate cancer screening blood test, the prostate-specific antigen (PSA), is coming from a decade-long prostate cancer research study in Europe.

Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
HORSHAM, Pa., April 2, 2012 /PRNewswire/ -- Grammy®-nominated singer, songwriter, producer and prostate cancer survivor Charlie Wilson and Janssen Biotech, Inc. are teaming up on Making Awareness a Priority: Putting Prostate Cancer on the M.A.P., a new program designed to raise awareness among African-American men and their families about prostate cancer and its disproportionate impact on the African-American community.  With the highest incidence of prostate cancer of any race in the U.S., African-American men are 2.4 times more likely to die from the disease than Caucasian men.  Making Awareness a Priority (M.A.P.) brings together leading voices in advocacy and health education through live events in select cities across the country.  ...

Does CyberKnife® Radiosurgery for Prostate Cancer Add Up?
NEW YORK, March 29, 2012 /PRNewswire/ -- As it turns out, new-to-the-market CyberKnife® Robotic Radiosurgery by Accuray is not robotic surgery at all. Rather, in the treatment of prostate cancer, CyberKnife® uses targeted high-dose radiation to attack prostate cancer cells.